Erschienen in:
01.03.2010 | Letter to the Editor
Reply to the letter by Bedognetti et al. “Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era”
verfasst von:
Shigeru Kusumoto, Yasuhito Tanaka
Erschienen in:
International Journal of Hematology
|
Ausgabe 2/2010
Einloggen, um Zugang zu erhalten
Excerpt
Reactivation of hepatitis B virus (HBV) has been reported not only in hepatitis B surface antigen (HBsAg)-positive patients undergoing systemic chemotherapy, but also in a proportion of HBsAg-negative patients with antibody to HBsAg (anti-HBs) and/or antibody to hepatitis B core antigen (anti-HBc) [
1‐
4]. Recently, rituximab-plus-steroid combination chemotherapy (R-CHOP, etc.) has been identified as a risk factor for HBV reactivation in HBsAg-negative patients with malignant lymphoma [
2]. …